ST. LOUIS, January 23, 2025 /24-7PressRelease/ — Carl J. DeSelm, MD, PhD, has been selected for inclusion in Marquis Who’s Who. As in all Marquis Who’s Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.
Dr. DeSelm has established himself as a distinguished figure in the medical field through his dedicated work at Washington University School of Medicine in St. Louis. Holding the positions of assistant professor and principle investigator since 2018, he has been instrumental in developing innovative radiation treatments for pancreas cancer. Dr. DeSelm also treats cancer patients directly through his concurrent roles as a postdoctoral fellow and resident physician at Memorial Sloan Kettering Cancer Center. His commitment extends beyond patient care into the realm of research, as he runs a laboratory four days a week, playing a pivotal role in guiding individuals through the design and analysis of experiments, in addition to conducting his own research.
Prior to his current positions, Dr. DeSelm served as a resident physician at Barnes-Jewish Hospital, where he further enhanced the fundamental knowledge needed for his future health care roles. His career began as a general medicine intern at the Washington University School of Medicine in St. Louis. These early roles not only honed Dr. DeSelm’s clinical skills but also laid the foundation for his research endeavors.
A key area of Dr. DeSelm’s expertise is in developing CAR T cell therapies, a revolutionary approach that has significantly impacted the treatment of leukemia and lymphoma. His work demonstrating the synergistic effects of radiation therapy with CAR T cells has led to numerous clinical trials and is altering the standard care for these cancers. Furthermore, Dr. DeSelm’s recent research on developing CAR macrophage therapy for Alzheimer’s disease in mice represents a groundbreaking step towards creating new treatments for this debilitating condition.
Dr. DeSelm’s academic background is equally impressive. He received a bachelor’s degree in biochemistry and molecular biology from Dartmouth College in 2004, followed by a Medical Doctor from Washington University in St. Louis in 2009. Dr. DeSelm returned to Washington University in St. Louis to earn his PhD in molecular and cellular biology, bone biology, and immunology in 2012. He credits his success to the exceptional mentors he had throughout his education and career, emphasizing the transformative power of higher education and collaboration.
Beyond his professional achievements, Dr. DeSelm is actively involved in various civic organizations and committees, including serving as a clinical subcommittee member for grant reviews and as a core committee member of the cancer biology PhD program at Washington University in St. Louis. His contributions have been recognized with several awards, including being named a top doctor by Castle Connolly in 2020, receiving the Agilent National Early Career Professor Award, and earning the National Institute of Health Early Independence Award in 2018.
Outside of his professional life, Dr. DeSelm enjoys spending quality time with his spouse and three sons, playing soccer, bike riding in the park, and going on picnics. He is dedicated to continuing his work in academic medicine with the goal of advancing the drugs he is developing from laboratory models to human patients. This work promises to open new avenues for treating cancer and potentially Alzheimer’s disease in the coming years, an ambitious goal that exemplifies Dr. DeSelm’s commitment to life-changing research and improving the outcomes for patients of some of the most difficult diseases and conditions.
# # #
